Observational Study to Develop Dosing Chart (NCT04227171) | Clinical Trial Compass
CompletedNot Applicable
Observational Study to Develop Dosing Chart
South Korea534 participantsStarted 2018-08-03
Plain-language summary
To confirm the predictors based on patient specific characteristics and ovarian response and develop dosing chart when Follitropeā¢ PFS is administered to infertility women patients.
Who can participate
Age range19 Years ā 39 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female aged of 19 to 39 years
* Mean menstrual cycle in 25 to 35 days
* Patients to whom Follitrope PFS will be administered in those scheduled to undergo the IVF-ET according to the GnRH agonist or antagonist protocol
* In the past continuous IVF cycle failure less than 2 times
Exclusion Criteria:
* Patients having a history of ovarian, breast, uterus, hyperthalamus, or pituitary tumor
* Abnormal uterine bleeding of undetermined origin
* Prior hypersensitivity to a component of recombinant FSH
* Ovarian cyst or enlargement of undetermined origin
* Clinically significant endocrine abnormalities
* Patients having polycystic ovary syndrome (PCOS) history
* Poor Ovarian responder (Bologna criteria)
* Patients who received Clomiphene citrate, Letrozole (Pemara), or Gonadotropin within 30 days prior to enrollment in this study
What they're measuring
1
No. of oocytes retrieved No. of oocytes retrieved Number of oocyte retrieved